Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
RNN [AMEX]
Rexahn Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.15 Insider Own3.90% Shs Outstand176.67M Perf Week-7.79%
Market Cap125.44M Forward P/E- EPS next Y-0.10 Insider Trans0.38% Shs Float152.19M Perf Month-17.44%
Income-22.60M PEG- EPS next Q-0.02 Inst Own10.80% Short Float4.70% Perf Quarter-31.73%
Sales- P/S- EPS this Y-16.70% Inst Trans0.12% Short Ratio3.51 Perf Half Y-31.73%
Book/sh0.16 P/B4.44 EPS next Y28.60% ROA-102.40% Target Price2.83 Perf Year20.34%
Cash/sh0.23 P/C3.12 EPS next 5Y- ROE-160.70% 52W Range0.36 - 1.85 Perf YTD39.22%
Dividend- P/FCF- EPS past 5Y4.90% ROI- 52W High-61.31% Beta1.20
Dividend %- Quick Ratio45.40 Sales past 5Y- Gross Margin- 52W Low98.81% ATR0.04
Employees16 Current Ratio45.40 Sales Q/Q- Oper. Margin- RSI (14)34.02 Volatility7.95% 4.91%
OptionableNo Debt/Eq0.00 EPS Q/Q-800.00% Profit Margin- Rel Volume0.52 Prev Close0.71
ShortableYes LT Debt/Eq0.00 EarningsNov 04 Payout- Avg Volume2.04M Price0.72
Recom2.00 SMA20-11.15% SMA50-17.15% SMA200-14.43% Volume652,482 Change0.80%
28-Dec-12Initiated Burrill Institutional Research Mkt Outperform $1
18-Jan-12Resumed Rodman & Renshaw Mkt Perform
16-Jun-11Resumed Brean Murray Buy $3
02-Dec-10Initiated Brean Murray Buy $3
18-Jul-14 09:00AM  Rexahn Pharmaceuticals Provides Update on Phase I Supinoxin Trial in Cancer Patients with Solid Tumors Business Wire
16-Jun-14 06:52AM  What Falling Estimates & Price Mean for Rexahn Pharmaceuticals (RNN) Zacks
06:52AM  What Falling Estimates & Price Mean for Rexahn Pharmaceuticals (RNN)
09-Jun-14 04:21PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
04:21PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
23-May-14 04:41PM  Rexahn files $150M mixed securities shelf at theflyonthewall.com
04:41PM  Rexahn files $150M mixed securities shelf
21-May-14 12:18PM  REXAHN PHARMACEUTICALS, INC. Financials EDGAR Online Financials
12:18PM  REXAHN PHARMACEUTICALS, INC. Financials
16-May-14 08:25AM  Rexahn Pharmaceuticals (RNN) Jumps: Stock Surges 19.2% Zacks
08:25AM  Rexahn Pharmaceuticals (RNN) Jumps: Stock Surges 19.2%
15-May-14 09:08AM  Rexahn sees cash, cash equivalents balance sufficient to fund company into 1H16 at theflyonthewall.com +19.77%
09:08AM  Rexahn sees cash, cash equivalents balance sufficient to fund company into 1H16
09:06AM  Rexahn reports Q1 EPS (9c), consensus (2c) at theflyonthewall.com
09:06AM  Rexahn reports Q1 EPS (9c), consensus (2c)
09:00AM  Rexahn Pharmaceuticals Reports First Quarter 2014 Financial Results and Pipeline Update Business Wire
09:00AM  Rexahn Pharmaceuticals Reports First Quarter 2014 Financial Results and Pipeline Update
14-May-14 05:08PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online +8.86%
05:08PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
05:07PM  Rexahn Pharmaceuticals: An Undervalued Oncology Play With Risk Diversification at Seeking Alpha
05:07PM  Rexahn Pharmaceuticals: An Undervalued Oncology Play With Risk Diversification
08-May-14 09:04AM  Rexahn announces additional RX-3117 preclinical studies data at theflyonthewall.com
09:00AM  Rexahn Announces Additional Data from Preclinical Studies of RX-3117 Business Wire
21-Apr-14 04:23PM  Success Of Rexahn's Nano-Sized Taxotere Can Help Big Pharma Ease Patent Cliff at Seeking Alpha
09:01AM  Rexahn presents data from preclinical studies of RX-21101 theflyonthewall.com
09:00AM  Rexahn Presents Data from Preclinical Studies of RX-21101 Business Wire
02-Apr-14 09:00AM  Rexahn Pharmaceuticals to Present Data on RX-3117 and RX-21101 at the 2014 American Association for Clinical Research Annual Meeting Business Wire +12.28%
27-Mar-14 01:04PM  REXAHN PHARMACEUTICALS, INC. Financials EDGAR Online Financials
24-Mar-14 08:15AM  Rexahn sees complete RX-3117 Phase I enrollment in 4Q14-early FY15 theflyonthewall.com
08:00AM  Rexahn Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights Business Wire
21-Mar-14 04:19PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report EDGAR Online
19-Mar-14 06:00AM  3 Stocks Under $10 Making Big Moves at TheStreet
17-Mar-14 08:00AM  Rexahn Pharmaceuticals to Present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York Business Wire
15-Mar-14 03:15PM  This Week in Biotech: NW Bio Soars While Geron Goes Geronimo at Motley Fool
12-Mar-14 04:30PM  Phase I Data on Rexahn's Supinoxin Zacks
04:30PM  Phase I Data on Rexahn's Supinoxin
11-Mar-14 02:59PM  Why Rexahn Pharmaceuticals Inc. Jumped Higher at Motley Fool
02:59PM  Why Rexahn Pharmaceuticals Inc. Jumped Higher
08:00AM  Rexahn Announces Initial Results from Phase I Trial of SupinoxinTM (RX-5902) for Solid Cancer Tumors Business Wire
08:00AM  Rexahn Announces Initial Results from Phase I Trial of SupinoxinTM (RX-5902) for Solid Cancer Tumors
07-Mar-14 10:49AM  Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine at TheStreet -8.33%
10:49AM  Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine
06:00AM  Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine at TheStreet
04-Mar-14 08:00AM  Rexahn Pharmaceuticals to Present at the 26th Annual ROTH Conference Business Wire
08:00AM  Rexahn Pharmaceuticals to Present at the 26th Annual ROTH Conference
03-Mar-14 04:16PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Optionetics +5.19%
04:16PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and EDGAR Online
08:00AM  Rexahn Pharmaceuticals Appoints Mark Carthy to Board of Directors Business Wire
08:00AM  Rexahn Pharmaceuticals Appoints Mark Carthy to Board of Directors
27-Feb-14 12:14PM  Rexahn Pharmaceuticals: Another $1.30 Biotech Lottery Ticket at Seeking Alpha +10.66%
12:14PM  Rexahn Pharmaceuticals: Another $1.30 Biotech Lottery Ticket
06-Feb-14 03:15PM  5 Stocks Under $10 Set to Soar at TheStreet +7.77%
04-Feb-14 08:00AM  Rexahn Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference Business Wire
08:00AM  Rexahn Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference
31-Jan-14 02:16PM  Following Unmet Needs To Biotech Profits: Echo He at Seeking Alpha
02:16PM  Following Unmet Needs To Biotech Profits: Echo He
27-Jan-14 02:11AM  Rexahn Pharmaceuticals (RNN) Jumps: Stock Up 5.3% Zacks
02:11AM  Rexahn Pharmaceuticals (RNN) Jumps: Stock Up 5.3%
21-Jan-14 04:51PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
04:51PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013 at TheStreet
07:00AM  It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013
15-Jan-14 03:38PM  Rexahn Pharmaceutical Shares Are Still A Buy Despite Recent Volatility at Seeking Alpha -10.34%
03:38PM  Rexahn Pharmaceutical Shares Are Still A Buy Despite Recent Volatility
09:06AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and EDGAR Online
09:06AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
08:59AM  Rexahn Announces $20 Million Registered Direct Offering Business Wire
08:59AM  Rexahn Announces $20 Million Registered Direct Offering
08:26AM  3 Biotechs Getting Plenty Of Attention From Investors at Seeking Alpha
14-Jan-14 09:00AM  Rexahn Initiates Phase IIa Clinical Trial of Archexin┬« in Patients with Metastatic Renal Cell Carcinoma Business Wire -27.50%
09:00AM  Rexahn Initiates Phase IIa Clinical Trial of Archexin┬« in Patients with Metastatic Renal Cell Carcinoma
08:53AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
08:53AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
10-Jan-14 10:35AM  Why Rexahn Pharmaceuticals (RNN) Is Up Today at TheStreet +62.86%
10:35AM  Why Rexahn Pharmaceuticals (RNN) Is Up Today
09-Jan-14 04:20PM  Rexahn Pharma rises as analyst starts coverage AP +12.90%
04:20PM  Rexahn Pharma rises as analyst starts coverage
12:20PM  Rexahn's Replacement For Eli Lilly's Gemzar Enters New Clinical Trial at Seeking Alpha
12:20PM  Rexahn's Replacement For Eli Lilly's Gemzar Enters New Clinical Trial
08-Jan-14 08:00AM  Rexahn Initiates Phase Ib Clinical Trial of RX-3117 for Treatment of Solid Tumors Business Wire +5.08%
08:00AM  Rexahn Initiates Phase Ib Clinical Trial of RX-3117 for Treatment of Solid Tumors
07-Jan-14 08:00AM  Rexahn Pharmaceuticals to Present at the Biotech Showcase 2014 Business Wire +5.36%
08:00AM  Rexahn Pharmaceuticals to Present at the Biotech Showcase 2014
22-Dec-13 12:49PM  Rexahn: A Turn Around Story For 2014 at Seeking Alpha
12:49PM  Rexahn: A Turn Around Story For 2014
11-Dec-13 08:00AM  Rexahn Receives Method Patent for Treatment of Solid Tumor Cancers for Supinoxin TM (RX-5902) Business Wire +20.00%
08:00AM  Rexahn Receives Method Patent for Treatment of Solid Tumor Cancers for Supinoxin TM (RX-5902)
25-Nov-13 01:47PM  Rexahn's Akt-1 Inhibitor To Begin Phase II Trials For Kidney Treatment at Seeking Alpha +5.26%
01:47PM  Rexahn's Akt-1 Inhibitor To Begin Phase II Trials For Kidney Treatment
20-Nov-13 01:05PM  REXAHN PHARMACEUTICALS, INC. Financials EDGAR Online Financials
01:05PM  REXAHN PHARMACEUTICALS, INC. Financials
19-Nov-13 08:00AM  Rexahn Pharmaceuticals to Participate in Brean Capital 2013 Life Sciences Summit Business Wire
14-Nov-13 08:00AM  Rexahn Pharmaceuticals Reports Third Quarter Financial Results and Pipeline Update Business Wire
13-Nov-13 04:16PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online +10.53%
16-Oct-13 04:31PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and EDGAR Online
11-Oct-13 09:02AM  InPlay: Rexahn Pharmaceuticals announced it has received commitments from certain institutional investors to purchase an aggregate of $5.3 million of Rexahn's securities in an at market registered direct offering Briefing.com -5.66%
09:00AM  Rexahn Announces $5.3 Million At Market Registered Direct Offering Business Wire
10-Oct-13 08:29AM  Rexahn signs exclusive license agreement for Lipid-Coated Albumin Nanoparticle theflyonthewall.com
08:01AM  InPlay: Rexahn Pharmaceuticals in-licenses novel oligonucleotide targeted drug delivery platform from Ohio State University Briefing.com
08:00AM  Rexahn Pharmaceuticals In-Licenses Novel Oligonucleotide Targeted Drug Delivery Platform from Ohio State University Business Wire
Rexahn Pharmaceuticals, Inc., a development stage biopharmaceutical company, is engaged in the discovery, development, and commercialization of treatments for cancer and other medical needs. Its clinical stage oncology candidates comprise Archexin, an inhibitor of the protein kinase Akt, which has completed a Phase IIa clinical trials for the treatment of pancreatic cancer; RX-3117, a small molecule nucleoside compound with an anti-metabolite mechanism of action that is in Phase Ib clinical trials for the treatment of solid tumors; and RX-5902, a small molecule that inhibits the phosphorylation of p68 RNA helicase, which is in Phase I clinical trials for the treatment of solid tumors. The company's pre-clinical product pipeline consists of RX-0047-Nano, a nanoliposomal anticancer HIF-1 alpha inhibitor; and RX-21101, an anticancer nano-polymer drug. It has various collaborative research and development relationships with universities, research institutions, and other organizations, including Teva Pharmaceutical Industries, Ltd.; Korea Research Institute of Chemical Technology; The University of Maryland Baltimore; Ohio State University; Revaax Pharmaceuticals LLC; and Rexgene Biotech Co., Ltd. The company is based in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ahn Chang HoDirectorJun 12Option Exercise0.80136,193108,9546,950,117Jun 16 07:48 PM
Ahn Chang HoDirectorJun 12Sale0.99136,193134,4366,813,924Jun 16 07:48 PM
McIntosh David MDirectorApr 14Option Exercise0.80125,000100,000125,000Apr 16 04:18 PM